Can Biomarkers Predict Severe COVID-19? A Appear at SAA, CRP, Ferritin, and PCT

As the COVID-19 pandemic unfolded, identifying patients at risk of severe illness became a critical require. Researchers investigated whether readily available biomarkers could help predict which hospitalized patients would deteriorate. This article examines the role of Serum Amyloid A (SAA), C-reactive protein (CRP), ferritin, and procalcitonin (PCT) in forecasting the progression of COVID-19.

The Search for Prognostic Biomarkers

Early in the pandemic, clinicians recognized the wide spectrum of COVID-19 severity, ranging from mild symptoms to critical illness. Rapidly changing disease courses highlighted the need for biomarkers that could aid in clinical decision-making and resource allocation. SAA, CRP, ferritin, and PCT were all considered potential candidates due to their roles in inflammation and immune response.

What are SAA, CRP, Ferritin, and PCT?

• Serum Amyloid A (SAA): An acute-phase protein produced by the liver in response to inflammation [1].
• C-Reactive Protein (CRP): Another acute-phase protein, also produced by the liver, that indicates inflammation throughout the body.
• Ferritin: A protein that stores iron, but also rises in response to inflammation and can be an indicator of immune activation.
• Procalcitonin (PCT): Primarily produced by the thyroid gland, PCT levels increase significantly in bacterial infections and can also be elevated in severe viral infections.

Study Findings: Limited Predictive Value

A recent study conducted in a Dutch cohort of hospitalized COVID-19 patients investigated the ability of these biomarkers to differentiate between patients who remained moderately ill and those who progressed to severe disease within the first seven days of hospitalization [1], [2]. The study included 133 patients and analyzed blood samples collected over the first week of hospitalization.

The results indicated that none of the biomarkers – SAA, CRP, ferritin, or PCT – were able to reliably predict which patients would develop severe COVID-19. Specifically, there were no significant differences in the concentrations of these biomarkers at the time of hospitalization between those who remained moderately ill and those who progressed to severe disease.

Receiver Operating Characteristic (ROC) curve analysis further confirmed the limited predictive ability of these biomarkers. The areas under the curve (AUC) were relatively low:

• SAA: 0.461
• CRP: 0.500
• PCT: 0.528
• Ferritin: 0.550

An AUC of 0.5 indicates that the biomarker has no discriminatory power.

Implications and Future Research

These findings suggest that, at least within the first week of hospitalization, SAA, CRP, ferritin, and PCT are not useful for predicting which COVID-19 patients will become severely ill. While these biomarkers can indicate inflammation, they do not appear to be specific enough to accurately forecast disease progression.

Further research is needed to identify more reliable biomarkers for early risk stratification in COVID-19. Investigating combinations of biomarkers, as well as exploring other potential indicators of immune dysfunction, may lead to improved predictive models. Understanding the dynamic changes in biomarker levels over the course of the illness, rather than relying on a single measurement at admission, could also prove valuable.

Key Takeaways

• SAA, CRP, ferritin, and PCT are biomarkers of inflammation often measured in COVID-19 patients.
• A recent study found these biomarkers did not predict which hospitalized patients would progress to severe COVID-19 within 7 days.
• Further research is needed to identify more accurate prognostic biomarkers for COVID-19.